Biological Signatures Resulting From Occupational Exposure to Complex Mixtures of PAHs (PAH-ProMetGen)
Primary Purpose
Metabolic Disturbance, Protein Deficiency, Genotoxicity
Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Characterization of early biological effects following exposure to PAHs
Sponsored by
About this trial
This is an interventional prevention trial for Metabolic Disturbance focused on measuring polycyclic aromatic hydrocarbons, metabolism, mixtures, occupational exposure, genotoxicity
Eligibility Criteria
Inclusion Criteria: Subjects ages 18 years or more Subjects occupationally exposed to PAHs since more than 3 months Having signed the informed consent recruited by the occupational health service Exclusion Criteria: Obesity (BMI>30) Subjects suffering cancers or metabolic diseases (diabetes, dyslipidemia, amino-acid diseases, renal or hepatic impairment) at the onset of the study. Subjects taking medications related to the above diseases at the onset of the study.
Sites / Locations
- CHU Grenoble AlpesRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Subjects occupationally exposed to PAHs
Arm Description
Outcomes
Primary Outcome Measures
Deregulation of blood proteins expression due to exposure to PAHs
Number of proteins up or down regulated in period of exposure versus after holidays
Deregulation of blood metabolites expression due to exposure to PAHs
Number of metabolites up or down regulated in period of exposure versus after holidays
Frequency of micronuclei measured due to exposure to PAHs
Frequency of cells containing micronuclei in period of exposure versus after holidays
Secondary Outcome Measures
Full Information
NCT ID
NCT05679544
First Posted
December 23, 2022
Last Updated
April 27, 2023
Sponsor
University Hospital, Grenoble
1. Study Identification
Unique Protocol Identification Number
NCT05679544
Brief Title
Biological Signatures Resulting From Occupational Exposure to Complex Mixtures of PAHs
Acronym
PAH-ProMetGen
Official Title
Biological Signatures (Proteomics, Metabolomics and Genotoxicity) Associated With Occupational Exposure to PAH Mixtures and Relation With Exposure Biomarkers: Support for the Derivation of Biological Limit Values
Study Type
Interventional
2. Study Status
Record Verification Date
April 2023
Overall Recruitment Status
Recruiting
Study Start Date
April 25, 2023 (Actual)
Primary Completion Date
October 2025 (Anticipated)
Study Completion Date
October 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Grenoble
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This research project aims at better understanding the early biological effects resulting from occupational exposure to complex Polycyclic Aromatic Hydrocarbon (PAH) mixtures.
Current biomarkers used as part of biomonitoring campaigns are biomarkers of exposure, not numerous and poorly related to health effects.
The aim of this study is thus to improve our understanding of biological consequences of such exposures, both in terms of proteins deregulation, metabolism deregulation and genotoxicity.
Detailed Description
PAHs are ubiquitous pollutants inducing several diseases, among which cancer is the most significant endpoint, with increased incidences of lung, skin, and bladder cancers. PAHs induce genotoxic effects (sister chromatids exchange, micronuclei, DNA damage) but require metabolic activation in humans as indirect-acting carcinogens. Thus, the knowledge of metabolic pathways involved following PAH exposure is critical for understanding and preventing cancer risks. Besides, exposure to PAHs is assumed to induce other adverse health effects (diabetes, inflammation, infertility, cardiovascular disease). Unfortunately, early disease-related biomarkers are still largely unknown and our comprehension about the mechanisms involved is still limited. The rare existing biological limit values either refer to not carcinogenic PAH (pyrene) or detoxification pathways (3-OHBaP for BaP), although new biomarkers reflecting the genotoxic pathway of BaP (TetraolBaP) are now available. There is thus a need for identifying more relevant biomarkers of exposure / effect, and for a better understanding of the biological consequences resulting from PAH exposures as well as the associated metabolic pathways involved.
The objectives of the project are :
To better understand and characterize molecular, metabolic and genotoxic impacts resulting from exposure to PAHs and to link such impacts with biological levels of various PAH metabolites,
To study the influence of BaP metabolism (genotoxic versus detoxication pathway) on the differential expression of metabolites / proteins and on genotoxicity endpoints in order to get relevant data for deriving new biological limit values,
To elucidate the associations between omics deregulations due to PAH exposures and activated metabolic pathways, in order to define candidate effect biomarkers for human biomonitoring.
The originalities of the project are the following. First, this is a human study performed in real occupational settings on workers exposed to representative PAH mixtures. It is a multidisciplinary approach simultaneously combining up-to-date biomonitoring, omics and cytogenetics analyses, that will give insight into a comprehensive view of metabolic reactions and protein expressions following occupational exposure to PAH mixtures, and allow the identification of the biological processes involved. Carcinogenic BaP metabolites (Tetraol-BaP and 3-OHBaP) will be simultaneously analyzed in order to compare the two main metabolic pathways of BaP.
The main steps of the projects will be :
Recruitment of 100 workers differentially exposed to PAH mixtures sampled across two time periods (after weeks of exposure and following 3 weeks without occupational exposure),
Recording of relevant data (work characteristics, jobs / tasks, working experience, number of years of exposure, smoking habits, nutritional intake, co-morbidity),
Toxicological analyses (LC-Fluorescence and GC-MS-MS) of urinary metabolites of several gaseous and particulate PAHs (Naphtalene, Fluorene, Phenanthrene, Pyrene, BaP, BeP, Chrysene, Benzo(b)Fluoranthene, Benzo(k)Fluoranthene, Benzo(a)Anthracene),
Proteomics analyses on blood samples through an enrichment approach for a bottom-up label free quantitative proteomic analysis based LC-HR-MS. Deregulated proteins (DEP) will be identified and the associated protein signature. A gene ontology (GO) analysis will define the groups of biological processes involved,
Untargeted Metabolomics analyses on blood samples in UHPLC-HR-MS, with unsupervised statistical analyses (Principal Component Analysis, Logistic Regressions), identification of relevant metabolites by their comparison to the Human Metabolome database, and advanced molecular networking / spectral library search of LC-MSMS data,
Micronuclei (MN) in buccal cells through the harvesting of buccal cells using a cytobrush, transfer to the lab in a buffer, fixing and staining, automatic counting under fluorescent light.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Metabolic Disturbance, Protein Deficiency, Genotoxicity
Keywords
polycyclic aromatic hydrocarbons, metabolism, mixtures, occupational exposure, genotoxicity
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
100 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Subjects occupationally exposed to PAHs
Arm Type
Experimental
Intervention Type
Biological
Intervention Name(s)
Characterization of early biological effects following exposure to PAHs
Intervention Description
Biological samples collected in period of exposure and after holidays
Primary Outcome Measure Information:
Title
Deregulation of blood proteins expression due to exposure to PAHs
Description
Number of proteins up or down regulated in period of exposure versus after holidays
Time Frame
up to 6 months between both periods of study
Title
Deregulation of blood metabolites expression due to exposure to PAHs
Description
Number of metabolites up or down regulated in period of exposure versus after holidays
Time Frame
up to 6 months between both periods of study
Title
Frequency of micronuclei measured due to exposure to PAHs
Description
Frequency of cells containing micronuclei in period of exposure versus after holidays
Time Frame
up to 6 months between both periods of study
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Subjects ages 18 years or more
Subjects occupationally exposed to PAHs since more than 3 months
Having signed the informed consent
recruited by the occupational health service
Exclusion Criteria:
Obesity (BMI>30)
Subjects suffering cancers or metabolic diseases (diabetes, dyslipidemia, amino-acid diseases, renal or hepatic impairment) at the onset of the study.
Subjects taking medications related to the above diseases at the onset of the study.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Renaud PERSOONS, PhD, Pharm D
Phone
00 33 4 76 76 51 78
Email
RPersoons@chu-grenoble.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Christine DEMEILLIERS, PhD
Phone
00 33 4 76 63 75 01
Email
christine.demeilliers@univ-grenoble-alpes.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Renaud PERSOONS
Organizational Affiliation
University Hospital, Grenoble
Official's Role
Principal Investigator
Facility Information:
Facility Name
CHU Grenoble Alpes
City
Grenoble
ZIP/Postal Code
38043
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Renaud Persoons
Phone
04 76 76 51 78
Email
RPersoons@chu-grenoble.fr
First Name & Middle Initial & Last Name & Degree
Christine Demeilliers
Phone
04 76 63 75 01
Email
christine.demeilliers@univ-grenoble-alpes.fr
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Biological Signatures Resulting From Occupational Exposure to Complex Mixtures of PAHs
We'll reach out to this number within 24 hrs